Oncotarget

Clinical Research Papers:

Effect of metformin on kidney function in patients with type 2 diabetes mellitus and moderate chronic kidney disease

Wei-Hao Hsu, Pi-Jung Hsiao, Pi-Chen Lin, Szu-Chia Chen, Mei-Yueh Lee _ and Shyi-Jang Shin

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:5416-5423. https://doi.org/10.18632/oncotarget.23387

Metrics: PDF 1714 views  |   HTML 3283 views  |   ?  


Abstract

Wei-Hao Hsu1,2, Pi-Jung Hsiao1,3, Pi-Chen Lin1, Szu-Chia Chen2,3,4,5, Mei-Yueh Lee1,2,3,4 and Shyi-Jang Shin1,3,6

1Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

2Department of Internal Medicine, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

3Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

4Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

5Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

6Center for Lipid and Glycomedicine Research, Kaohsiung Medical University, Kaohsiung, Taiwan

Correspondence to:

Mei-Yueh Lee, email: lovellelee@hotmail.com

Keywords: metformin; diabetes mellitus; chronic kidney disease; renal function decline; estimated glomerular filtration rate

Received: September 12, 2017     Accepted: December 04, 2017     Published: December 17, 2017

ABSTRACT

Background: Impaired renal function can lead to the accumulation of metformin, and elevated concentrations of metformin have been associated with lactic acidosis. The aim of this study was to evaluate the effect of continuous metformin treatment in patients with type 2 diabetes mellitus (DM) and moderate chronic kidney disease (CKD) (estimated glomerular filtration rate (eGFR) 30–0 ml/min/1.73 m2) on renal function.

Methods: A total of the 616 patients were enrolled from the research database of Kaohsiung Medical University Hospital from January 1 to 2009 and December 31, 2013. The patients were divided into two groups: those who continued metformin treatment (continuation group; n = 484), and those who discontinued metformin treatment for at least 100 days (interruption group; n = 132).

Results: The slope of eGFR in the metformin interruption group was statistically lower than that in the metformin continuation group (0.75 ± 0.76 vs. –1.32 ± 0.24 mL/min/1.73 m2/year, p = 0.0007). After adjusting for baseline covariates in the multivariate linear regression analysis, the continuation of metformin (unstandardized coefficient β, –2.072; 95% confidence interval, –3.268– –0.876) was a risk factor for the patients with DM and moderate CKD.

Conclusions: Metformin may have an adverse effect on renal function in patients with type 2 DM and moderate CKD.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 23387